Results | Of total 9361 patients in SPRINT, 3054 were 70 years or older and met the inclusion criteria, of whom 1350 (44.2%) were taking statins at baseline. Those on statins, compared with those not on statins, had significantly lower Framingham risk scores but were more likely to be male, have chronic kidney disease, higher body mass index, and higher glucose ( Table 1) . There was no significant difference in primary event rates with or without statin use at baseline: 0.064 vs 0.078 over trial (absolute rate reduction, 0.014; P = .14).
In Table 2 , the results of models adjusting for nonrandom assignment of statin use are shown. In the treatment effects IPW model, among patients 70 years or older, the average event rates with and without statin use at baseline were 0.063 vs 0.081, equivalent to an absolute risk reduction of 0.018 over the trial (P = .13). In the survival IPW model, the average time to event with and without statin use at baseline were 669.2 vs 735.8 days, a decrease of 84.6 days (P = .22) and thus an increased hazard rate.
Changing age thresholds to 65 years or older did not materially alter these results (Table 2) , nor did restricting analyses to BP management arms, using a Weibull censoring function in IPW models, a propensity score matched treatment effects model, logistic regression, or simpler Cox models that did not adjust for nonrandom statin use.
Discussion | Participants in the SPRINT trial 65 or 70 years or older without diagnosed CVD who were taking statins at baseline had no significant differences in primary outcomes compared with those not taking statins with or without adjustment for nonrandom statin use. These nonrandomized results contradict randomized trials of statins such as JUPITER This study is limited by its reliance on a nonrandomized comparison and secondary analysis for which the original trial was not powered, a lack of time-varying data on statin use, and the potential inadequacy of conditioning only on observed variables to model the nonrandom assignment of statin use. Moreover, given low event rates, even in a 1-sided test of the crude primary event rates, smaller differences than 3% cannot be distinguished; while for a 1-sided test of times to primary event, reductions in the hazard ratio less substantial than 0.77 cannot be distinguished.
We still do not have sufficient numbers of primary prevention trials to make strong recommendations about statins in intermediate-risk populations (6%-12% 10-year risk), at least on the basis of survival. Yet even in this relatively high-risk older adult population (22%-25% 10-year risk), significant reductions in cardiovascular events were not found.
Accordingly, until the Australian STAREE randomized trial (NCT02099123) of statin use among older adults concludes, 1 this study lends some support to the concerns increasingly raised about benefits and harms of statins among older adults at higher risk of CVD.
Generic Substitution Rates of Oral Contraceptives and Associated Out-of-Pocket Cost Savings Between January 2010 and December 2014
Over one-quarter of women in the United States of reproductive age have used oral contraceptives (OCPs).
1 While most OCPs are available as generics, utilization of generic OCPs and 6 We excluded entries that were prescribed to individuals older than 55 years, did not have a valid NDC, or reported no total cost. This research was not performed on human participants, so institutional review approval was not necessary. Average per person per year (PPPY) generic and brand out-of-pocket costs were determined among individuals prescribed only generic or only brand OCPs in a given year. The 4% of individuals who received brand and generic OCPs during a given year were excluded to prevent switching OCPs from confounding PPPY cost. We estimated the out-of-pocket savings of switching from brand to generic OCPs assuming the same utilization pattern of generic drugs and constant prices, by calculating the weighted mean difference PPPY between brand-name drug costs and our market basket of generic drugs. The weight of each individual is assigned in the MEPS data set.
All expenditures were converted to 2014 dollars by using Bureau of Labor Statistics medical price index.
Results | The study population consisted of 19 944 OCP prescribing events for 3086 individuals from January 2010 to December 2014 who represent 49.8 million women nationally. Median (interquartile range) age was 28 (22-35) years; white women comprised 75.6% (n = 2334) of the population, and Hispanic women comprised 19.7% (n = 609) (Table) .
Generic OCP prescribing increased from 73% in 2010 to 82% in 2014. Brand OCPs represented a disproportionate proportion of total OCP expenditures, accounting for 24% of all prescriptions between 2010 and 2014 but 42% of total expenditures ( Figure) . Of all brand OCP prescriptions, 97.4% had generic options available.
For generic OCPs, average out-of-pocket cost PPPY was $59.53 (total PPPY cost, $163.24). For brand OCPs, average outof-pocket cost PPPY was $117.15 (total PPPY cost, $427.06). Brand prescriptions had longer pill days PPPY than generics (289 d [95% CI, vs 244 d [95% CI, 234-255]; P < .001). The percent of OCP prescriptions with no copay increased from 14.4% between 2010 and 2011 prior to the Affordable Care Act (ACA) contraceptive mandate to 47.0% between 2012 and 2014 post-ACA contraceptive mandate (P < .001). Assuming constant prices, substituting generic OCPs for brand when generic options were available would have saved $751 million in out-of-pocket costs during the study years.
Discussion | That we know of, this is the first study to date to examine OCP generic substitution rate and estimate potential savings of switching from brand to generic OCPs using a nationally representative sample in the post-ACA landscape. 
Letters
While brand OCP prescribing has declined, its share of total spending has not decreased, reflecting a possible increase of the relative price of brand OCPs to generic OCPs. The potential out-of-pocket savings from prescribing generic instead of brand OCPs are significant. Our study is limited by a lack of data on off-label prescribing of OCPs and pharmaceutical rebates, which are not accounted for in the MEPS. These results underscore the foregone opportunities of generic prescribing as a strategy to reduce health care costs and highlight the challenges in promoting generic OCP prescribing. Prescribed indicates the percentage of all prescriptions within a given year; expenditure, the percentage of total expenditure within a given year. Out-of-pocket expenditures follow a similar pattern (data not shown). 
